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Piroxicam suppositories were prepared by using water soluble and oil soluble 
suppository bases. All the prepared suppositories were evaluated for various 
physical parameters like weight variation, drug content and hardness, melting 
point, disintegration and macromelting range. Invitro release study was 
performed USP type I apparatus using Sorensen's phosphate buffer pH 7.4 as 
dissolution media. The suppositories prepared with water soluble bases were 
within permissible range of all physical parameters. In vitro drug released 
from water soluble bases (hydrous PEG and anhydrous PEG) was greater 
than that from oil soluble bases. 
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Rectal drug delivery has a number of advantages such 
as reduced hepatic first pass elimination of high 
clearance drugs, avoidance of gastric irritation 
associated with certain drugs in case of nausea, 
vomiting and when the patient is unconscious. Rectal 
route of administration is specifically useful for 
infants and children who have difficulty in 
swallowing oral medicine. Drug administered in 
suppository form can produce not only local effect 
but also systemic therapeutic action [1]. Suppositories 
can be prepared by using lipophilic bases or by 
hydrophilic bases [2-4]. These suppositories melt or 
dissolve in body fluids and release the drug.  
Piroxicam, 4-hydroxyl-2-methyl-N-2-pyridinyl-2H-
1,2,-benzothiazine-3-carboxamide 1,1-dioxide [5], a 
potent nonsteroidal antiinflammatory agent (NSAIA), 
has been used effectively in the management of 
moderate to severe rheumatoid arthritis, ankylosing 
spondilytis,  osteoarthritis and acute gouty arthritis [6,  
 
7]. Like other NSAIDs, piroxicam causes irritation, 
nausea, anorexia, gastric bleeding and diarrhea when 
given orally [7]. Consequently, an alternate route of 
administration to avoid or minimize the above side 




 Piroxicam was procured from Pfizer company Cairo 
(Egypt), Polyethylene glycol 400, 6000 (Union 
Carbide, new York);Witepsol H5, Witepsol H15, 
Witepsol W35 and  Witepsol E75 (Dynamit Noble, 
Germany); Suppocire AML, Suppocire AM (Gatte 
Fosse, France); NovataDE75(Hankel International 
Düsseldorf , Germany); Cacao butter BP grade; 
Disodium hydrogen phosphate and potassium 
dihydrogen phosphate (EL-Naser pharmaceutical 
chemical Co. Egypt). All other chemicals used were 
of analytical grade. 
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Methods  
Preparation of piroxicam suppositories 
Suppositories weighing 2 gm each , containing 20 mg 
of  piroxicam was prepared using water soluble bases 
namely Anhydrous polyethylene glycol base(a 
mixture of carbowaxes 400 and 6000(4:6),Hydrous 
polyethylene glycol base(a mixture of carbowaxes 
400 , 6000 and water (2:6:2) and oil soluble bases 
namely adeps solidus bases (Witepsol 
H5,H15,W35,E75 ,Suppocire AML, AM, cacao butter 
and NovataDE75) by cream melt technique taking in 
to account the displacement value of piroxicam in 
each base using stainless steel moulds [8]. The 
prepared suppositories were wrapped in aluminum 




The prepared suppositories were evaluated for official 
and unofficial parameters viz weight variation, 
content uniformity, hardness, melting point, 
dissolution test, disintegration and Macro-melting 




All the suppositories (made by the respective bases), 
were weighed and average weight was calculated. 
Then all the suppositories were individually weighed 
and the variation from the average was calculated. 
 
Content uniformity 
Piroxicam, practically insoluble in water, is soluble in 
equal mixture of phosphate buffer pH 7.2 and 
methanol. Three randomly selected suppositories 
were taken in 1000 ml standard flask containing 100 
ml mixture of phosphate buffer pH 7.2 and methanol 
(50:50).The flask was shaken for desired period of 
time to dissolve the drug from suppositories. 
Absorbance of the resulting solutions after 
appropriate dilutions was measured on Shimadzu 
PR240,Kyoto, Japan UV/Vis spectrophotometer at 
354 nm against the blank prepared using respective 
suppositories without drug 
 
Hardness (fracture point) 
Hardness of the prepared suppositories was tested 
using Erweka hardness tester model PTW, Germany). 
The weight required for suppository to collapse was 
taken as measure of hardness of the suppository. 
Hardness test or fracture point test was carried to 
determine the tensile strength of the suppositories to 
access whether they will be able to withstand the 
hazards of packing and transporting. 
 
Melting point 
The ascending melting point method was used to 
determine the melting point of each type of suppositories. 
Capillary tubes,10 cm in length , sealed at one end, were 
filled with the formulation  to about 1cm height, then  
was dipped in gradually heated electro-thermal 
thermometer (Seti ,Cairo  ,Egypt). 
 
Disintegration and macro-melting range test 
The disintegration test was performed on six 
suppositories of each type using USP tablet 
disintegration (Model PTW, Germany) test apparatus.  
160ml of distilled water was used as medium at 37oc. 
suppositories prepared with water soluble bases the 
time required for complete disintegration and in case 
of oily bases, the time required for complete melting 
of suppository was determined. 
 
Dissolution Test 
Dissolution test was carried out in USP rotating 
basket dissolution apparatus (Pharmatest, Type PTW 
Germany) using 900ml of Sorensen's phosphate 
buffer of pH 7.4. . Rotation speed was controlled at 
50 rpm while temperature was maintained at 
37±0.5°c. 
Two milliliter aliquots of the dissolution fluid were 
withdrawn at specified interval from the reservoir and 
each time replaced with equal volume of fresh 
dissolution medium. Withdrawn samples were 
suitably diluted and analyzed using Shimadzu PR240, 
Kyoto, Japan at 354nm. Linear relation was obtained 
by plotting the absorption against the concentration of 
Piroxicam in Sorensen's phosphate buffer pH 7.4 at 
different time intervals with equation 
Y=0.05845X+0.001(r=0.99998). 
 
Results and discussion 
The physical parameters of the prepared Piroxicam 
suppositories are shown in table 1. The weight 
variation and content uniformity of the prepared 
suppositories complied with British pharmacopoeia. 
The   percentage   of deviation   of   all   the   prepared  
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Figure 1. In-vitro release of piroxicam from different suppository base. 
 
 
The percentage drug contents of all the suppositories 
formulations was found to be between 92.15%±0.75 - 
103.40%±1.23 which complied with the limits 
established in the pharmacopoeia (British 
Pharmacopoeia). All the formulated suppositories 
complied the disintegration time limit for 
suppositories as per pharmacopoeia except the 
suppositories prepared with NovataDE75 (>60min.). 
Results showed the piroxicam decreased 
disintegration time in comparison to the plain base 
(control suppositories without piroxicam) in all 
formulation with exception of mixture of (Witepsol 
W35 and Witepsol E75). Regarding the effect of 
piroxicam on the hardness of suppositories prepared 
from different bases (table 1). It is clear that the 
hardness values of the tested suppositories range from 
(2.2±0.1 to 4 ±0.1 Kg.) with exception of 
NovataDE75 (>6.2± 0.1 Kg). Witepsol H15 has the 
lowest value (2.2 Kg.) and hydrous PEG has the 
highest value (4.0 Kg.).The inclusion of piroxicam 
moderately increased the hardness of base with 
exception of Witepsol H15, cacao butter, Witepsol 
W35 and mixture of (Suppocire AML + Suppocire 
AM) showed slight decrease in hardness value. In 
case of Suppocire AM the incorporation of piroxicam 
did not affect the hardness. 
Melting range and liquefaction time values are shown 
in table 1, from these results the suppository bases 
can be arranged with respect to melting point 
according to the following order, Cacao butter (33°C) 
<Suppocire AML = Witepsol H15(34.5°C) < 
Witepsol W35(35°C)< mixture of (Suppocire AML + 
Suppocire AM)= mixture of (Witepsol W35 and 
Witepsol E75=Witepsol H5(35.5°C) < Suppocire AM 
(36°)< Witepsol E75(39°C)< hydrous PEG(41°C)< 
NovataDE75(42°C)< anhydrous PEG(42.5°C). it is 
needless to say that piroxicam has a slight effect on 
the melting point of the most bases used. Release data 
of piroxicam from deferent suppository bases in 
Sorensen's phosphate buffer pH 7.4 is graphically 
illustrated in Figure 1. From the data obtained it is 
clear that the amount of the drug released from water 
soluble bases (hydrous PEG and anhydrous PEG) is 
greater than that from adeps solidus bases. This 
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enhancement of the dissolution was due to enhanced 
solubility of the piroxicam by water-soluble bases. 
This is due to PEG bases have good hydrophilic 
property and solubilizing effect [13-15]. Concerning 
the water soluble bases (PEG bases) the release of the 
medicament from hydrous base was higher than that 
from the anhydrous ones, as the release after 3 hours 
was found to correspond to 100 and 68.40% from 
hydrous and anhydrous suppository bases 
respectively. According to the release pattern of 
piroxicam ,the tested adeps solidus suppository bases 
can be arrange as follows: Suppocire AML> mixture 
of (Suppocire AML + Suppocire AM)> Witepsol 
H15>cacao butter > Witepsol W35> mixture of 
(Witepsol W35 and Witepsol E75)> Witepsol E75> 
Suppocire AM> NovataDE75> Witepsol H5 (figure 
1). This arrangement indicates that the release of drug  
was found higher from bases with low melting range 
than from those of comparatively higher melting  
range  with the exception of cacao butter. Thus 
Suppocire AML with lowest melting range (33-36°C) 
gave the highest amount of drug released (71.2%) 
followed by Witepsol H15 melting range (34-36°C), 
which released about (26.2%) of piroxicam after 3 
hours. The lowest amount of drug released was 
observed in case of NovataDE75, which exhibited the 
highest melting range (41-43°C).Thus it could be 
concluded that softening point of these suppositories 
was the rate limiting step in release of drug from fatty 
bases. The cacao butter has low melting range (32-
35° C )   but   it   gave  slightly    lower     release    of  
medicament compared with Suppocire AML and 
Witepsol H15.This is attributed due to the presence of 
monoglycerides in the latter bases which acts as 
emulsifying agent ,thus facilitating the dispersion of 
the medicament to the surrounding media.  
 
 
Table 1: Evaluation of piroxicam suppositories for various parameters (n=3) 
 
  Melting liquefaction Disintegration time 
(minutes) Time(min.) Range(°C) 
Hardness 
(Kg) 
FM C FM C FM C FM C 
Suppository base 
13.0 14.0 8.0 10.0 39 - 46 40 - 41 3.6 3.2 Anhydrous PEG 
13.0 15.0 12.60 12.0 39 - 43 42 - 43 4.0 3.9 Hydrous PEG 
9.0 11.2 8.0 9.0 34 - 36 34 - 36 2.2 2.4 Witepsol H15 
26.0 32.5 43.0 42.0 38- 40 37 - 39 2.8 2.4 Witepsol E75 
11.0 14.0 7.0 8.0 34 - 36 34 - 36 2.4 2.6 Witepsol W35 
13.0 16.0 8.70 .010 35 - 36 34 - 36 3.2 2.8 Witepsol H5 
4.0 6.0 5.0 .04 31 - 35 30 - 36 2.4 2.9 Cacao butter 
>60 >60 120> 120 41 - 43 40 - 42 >6 >6 NovataDE75 
4.5 13.4 3.0 .04 33- 36 35- 36 3.0 2.8 Suppocire AML 
7.0 8.7 6.0 8.0 35 - 37 34 - 37 2.6 2.6 Suppocire AM 
28.0 26.0 .024 .025 35 - 36 35 - 37 3.0 2.6 Mixture(4 +5) 
5.0 11.1 .010 .07 34 – 37 35- 36 3.2 3.8 Mixture(9+ 10) 
 
Mixture (5 +8) =Witepsol( E75+W35,1 :1), Mixture (9+ 10) =Suppocire (AML+AM, 1 :1), C=Control 
(suppository without piroxicam), FM=Fresh medicated suppository. 
 
Conclusion 
The release of piroxicam from water soluble bases 
was  found  higher than that from adeps solidus bases.  
 
The incorporation of water in PEG base enhanced the 
drug release. 
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